What is Crinetics Pharmaceuticals's D&A?

Crinetics Pharmaceuticals (CRNX) reported D&A of $1.16M in Q1 2026.

How has Crinetics Pharmaceuticals's D&A changed year-over-year?

Crinetics Pharmaceuticals's D&A increased by 25.4% year-over-year, from $925K to $1.16M.

What is the long-term trend for Crinetics Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's D&A has grown at a 43.3% compound annual growth rate (CAGR), from $922K to $3.89M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Crinetics Pharmaceuticals CRNX D&A

D&A at other companies

Neurocrine BiosciencesNBIX

$7.2M+9.1%

Corcept TherapeuticsCORT

$598K+29.4%

Catalyst PharmaceuticalCPRX

$70K-39.1%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

Mineralys Therapeutics, Inc.MLYS

$6K-60.0%

United TherapeuticsUTHR

$22.6M+14.1%

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's D&A?: Crinetics Pharmaceuticals (CRNX) reported D&A of $1.16M in Q1 2026.
How has Crinetics Pharmaceuticals's D&A changed year-over-year?: Crinetics Pharmaceuticals's D&A increased by 25.4% year-over-year, from $925K to $1.16M.
What is the long-term trend for Crinetics Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's D&A has grown at a 43.3% compound annual growth rate (CAGR), from $922K to $3.89M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.